Applications of Nanobiomaterials in the Therapy and Imaging of Acute Liver Failure
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Highlights: This review focuses on the therapeutic mechanisms, targeting strategies of various nanomaterials in acute liver failure, and recent advances of diverse nanomaterials for acute liver failure therapy, diagnosis, and imaging. This review provides an outlook on the applications of nanomaterials, especially on the new horizons in acute liver failure therapy, and inspires broader interests across various disciplines. Acute liver failure (ALF), a fatal clinical disease featured with overwhelming hepatocyte necrosis, is a grand challenge in global health. However, a satisfactory therapeutic option for curing ALF is still absent, other than liver transplantation. Nanobiomaterials are currently being developed for the diagnosis and treatment of ALF. The liver can sequester most of nanoparticles from blood circulation, which becomes an intrinsic superiority for nanobiomaterials targeting hepatic diseases. Nanobiomaterials can enhance the bioavailability of free drugs, thereby significantly improving the therapeutic effects in ALF. Nanobiomaterials can also increase the liver accumulation of therapeutic agents and enable more effective targeting of the liver or specific liver cells. In addition, stimuli-responsive, optical, or magnetic nanomaterials exhibit great potential in the therapeutical, diagnostic, and imaging applications in ALF. Therefore, therapeutic agents in combination with nanobiomaterials increase the specificity of ALF therapy, diminish adverse systemic effects, and offer a multifunctional theranostic platform. Nanobiomaterial holds excellent significance and prospects in ALF theranostics. In this review, we summarize the therapeutic mechanisms and targeting strategies of various nanobiomaterials in ALF. We highlight recent developments of diverse nanomedicines for ALF therapy, diagnosis, and imaging. Furthermore, the challenges and future perspectives in the theranostics of ALF are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Origin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
The Essential Medicinal Chemistry of Curcumin
Nelson, K. M., Dahlin, J. L., Bisson, J., Graham, J., Pauli, G. F., & Walters, M. A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00975 · Cited by 1,956
Immunological properties of engineered nanomaterials
Dobrovolskaia, M. A., & McNeil, S. E. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.223 · Cited by 1,823
Beyond oxidative stress: an immunologist's guide to reactive oxygen species
Nathan, C., & Cunningham-Bussel, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3423 · Cited by 1,619
Iron oxide MR contrast agents for molecular and cellular imaging
Bulte, J. W. M., & Kraitchman, D. L. (2004) · NMR in Biomedicine · doi:10.1002/nbm.924 · Cited by 1,500
Wang, Y.-X. J., Hussain, S. M., & Krestin, G. P. (2001) · European Radiology · doi:10.1007/s003300100908 · Cited by 1,381
Immune surveillance by the liver
Jenne, C. N., & Kubes, P. (2013) · Nature Immunology · doi:10.1038/ni.2691 · Cited by 1,047
Xiao, K., Li, Y., Luo, J., Lee, J. S., Xiao, W., Gonik, A. M., Agarwal, R. G., & Lam, K. S. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.01.021 · Cited by 1,039
In vitro Hepatic Differentiation of Human Mesenchymal Stem Cells
Lee, K., Kuo, T. K., Whang–Peng, J., Chung, Y., Lin, C., Chou, S., Chen, J., Chen, Y., & Lee, O. K. (2004) · Hepatology · doi:10.1002/hep.20469 · Cited by 865
Karlmark, K. R., Weiskirchen, R., Zimmermann, H. W., Gassler, N., Ginhoux, F., Weber, C., Merad, M., Luedde, T., Trautwein, C., & Tacke, F. (2009) · Hepatology · doi:10.1002/hep.22950 · Cited by 782
Sterile inflammation in the liver
Kubes, P., & Mehal, W. Z. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.09.008 · Cited by 666
Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes
Banas, A., Teratani, T., Yamamoto, Y., Tokuhara, M., Takeshita, F., Quinn, G., Okochi, H., & Ochiya, T. (2007) · Hepatology · doi:10.1002/hep.21704 · Cited by 555
Tan, C. Y., Lai, R. C., Wong, W., Dan, Y. Y., Lim, S.-K., & Ho, H. K. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt465 · Cited by 548
Functional integration of hepatocytes derived from human mesenchymal stem cells into mouse livers
Aurich, I., Mueller, L. P., Aurich, H., Luetzkendorf, J., Tisljar, K., Dollinger, M. M., Schormann, W., Walldorf, J., Hengstler, J. G., Fleig, W. E., et al. (2007) · Gut · doi:10.1136/gut.2005.090050 · Cited by 314
Lin, B., Chen, J., Qiu, W., Wang, K., Xie, D., Chen, X., Liu, Q., Peng, L., Li, J., Mei, Y., et al. (2017) · Hepatology · doi:10.1002/hep.29189 · Cited by 288
Bernsmeier, C., Pop, O. T., Singanayagam, A., Triantafyllou, E., Patel, V. C., Weston, C. J., Curbishley, S., Sadiq, F., Vergis, N., Khamri, W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.11.045 · Cited by 287
Huang, B., Cheng, X., Wang, H., Huang, W., la Ga hu, Z., Wang, D., Zhang, K., Zhang, H., Xue, Z., Da, Y., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0792-1 · Cited by 183
Self-citationDrug targeting to the diseased liver
Poelstra, K., Prakash, J., & Beljaars, L. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.02.011 · Cited by 172
Immunosuppression minimization vs. complete drug withdrawal in liver transplantation
Londoño, M.-C., Rimola, A., O’Grady, J., & Sanchez-Fueyo, A. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.003 · Cited by 118
Dysfunctional Immune Response in Acute-on-Chronic Liver Failure: It Takes Two to Tango
Martin-Mateos, R., Alvarez-Mon, M., & Albillos, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00973 · Cited by 116
Chen, C., Law, W., Aalinkeel, R., Nair, B., Kopwitthaya, A., Mahajan, S. D., Reynolds, J. L., Zou, J., Schwartz, S. A., Prasad, P. N., et al. (2012) · Advanced Healthcare Materials · doi:10.1002/adhm.201200094 · Cited by 82
Khamri, W., Abeles, R. D., Hou, T. Z., Anderson, A. E., El-Masry, A., Triantafyllou, E., Bernsmeier, C., Larsen, F. S., Singanayagam, A., Kudo, N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.023 · Cited by 49
Cited by
Liu, J., Liu, J., Mu, W., Ma, Q., Zhai, X., Jin, B., Liu, Y., & Zhang, N. (2024) · ACS Nano · doi:10.1021/acsnano.4c02380 · Cited by 74
Jin, Y., Zhang, J., Xu, Y., Yi, K., Li, F., Zhou, H., Wang, H., Chan, H. F., Lao, Y.-H., Lv, S., et al. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.05.001 · Cited by 55
“Excessive ROS, severe inflammation storm, and massive liver necrosis are the main pathological features of ALF [18,71].”
BackgroundSelf-citationLi, F., Wei, H., Jin, Y., Xue, T., Xu, Y., Wang, H., Ju, E., Tao, Y., & Li, M. (2023) · ACS Nano · doi:10.1021/acsnano.3c08495 · Cited by 23
Self-citation
Metadata
- Authors
- Jin, Y., Wang, H., Yi, K., Lv, S., Hu, H., Li, M., & Tao, Y.
- Venue
- Nano-Micro Letters
- Published
- 2020-11-19
- Volume
- 13
- Issue
- 1
- Pages
- 25-25
- ISSN
- 2150-5551 (ISSN-L)
- 2311-6706
- OpenAlex
- W3099567402
- Cited by
- 111
- References
- 24
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.